Kairos Pharma, Ltd. (KAPA): Cash & Equivalents
$4.49M
As of 2025-12-31
$2.63M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.49M | +253.1% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $1.27M | n/a | 2026-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Kairos Pharma, Ltd. (KAPA) | 2025-12-31 | $4.49M | +253.1% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $4.98M | n/m |
| Adial Pharmaceuticals, Inc. (ADIL) | 2025-12-31 | $5.88M | +56.8% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $3.09M | -44.0% |
| Greenwich LifeSciences, Inc. (GLSI) | 2025-12-31 | $6.18M | +51.0% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $3.06M | -16.8% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $1.8K | -16.3% |
| Matinas BioPharma Holdings, Inc. (MTNB) | 2025-12-31 | $4.00M | -45.1% |
| Ernexa Therapeutics Inc. (ERNA) | 2024-12-31 | $1.73M | -77.2% |
Compare KAPA, HIND, ADIL, GOVX side by side · Screen every company in Pharmaceutical Preparations ↗